Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Down 5.7% - Should You Sell?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) shares traded down 5.7% during trading on Monday . The company traded as low as $36.41 and last traded at $36.19. 266,106 shares changed hands during mid-day trading, a decline of 18% from the average session volume of 324,345 shares. The stock had previously closed at $38.37.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on SUPN shares. Cowen reaffirmed a "buy" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Piper Sandler restated a "neutral" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, Cantor Fitzgerald assumed coverage on shares of Supernus Pharmaceuticals in a research report on Monday, January 6th. They set an "overweight" rating and a $57.00 price objective on the stock.

Supernus Pharmaceuticals Trading Down 1.6 %

The firm's 50 day simple moving average is $37.33 and its 200 day simple moving average is $34.72. The firm has a market cap of $2.15 billion, a PE ratio of 36.31 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The company had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. During the same period in the prior year, the company earned ($0.29) earnings per share. The firm's revenue was up 14.2% on a year-over-year basis. As a group, equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current fiscal year.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 9.30% of the stock is currently owned by insiders.

Institutional Trading of Supernus Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its holdings in Supernus Pharmaceuticals by 97.1% during the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock valued at $25,000 after buying an additional 398 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after purchasing an additional 870 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock worth $61,000 after purchasing an additional 352 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new position in Supernus Pharmaceuticals during the 4th quarter worth $72,000. Finally, Venturi Wealth Management LLC bought a new stake in Supernus Pharmaceuticals during the 4th quarter valued at $92,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.